A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy (HAART).

Registry ID

EUCTR2006-006212-30

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Imperial College London

Start date

2007-08-09

Completion date

2011-10-03

Last update

2026-08-16

Conditions

• HIV-1

Summary

To investigate if immunological benefit can be induced in chronically infected HIV-1 patients by treatment with HAART supplemented with a vaccine and/or cytokines and hormones.

Locations

• , , UK

Related clinical trials

• Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
• Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
• CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
• Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
• Viral Infection of HSPC Impacts Hematopoiesis

View on source registry